From New London Day:

Pfizer pulls up stakes in NL

8-year-old, $300M campus to close; no job losses as operations will
consolidate in Groton
Eight years after opening its state-of-the-art global
research-and-development headquarters in New London, Pfizer Inc.
announced Monday it will close the nearly $300 million complex within
the next two years and consolidate local operations into its Groton campus.

The announcement that Pfizer will maintain its local work force numbers
came as the company said it will be closing six research-and-development
sites worldwide. About 1,400 positions in New London will be transferred
to Groton, where about 3,500 people work, Pfizer said. When Pfizer first
opened the New London campus, officials had said the complex could house
up to 2,000 associates.

"In Groton and New London, there will be a minimal headcount effect,"
said Martin Mackay, president of Pfizer's PharmaTherapeutics Research
and Development division, in a conference call. "Our presence in
Connecticut will be approximately the same ... it's about 5,000 now, and
that number will continue, though the makeup will change around the edges."

Pfizer earlier this year said nearly 20,000 jobs would be cut as a
result of its merger with the New Jersey-based Wyeth. The company said
Monday that about 15 percent of its overall R&D work force would be cut
as part of that downsizing.

***The announced closing of the New London site came as a blow to a city
that had counted on Pfizer to help revive its fortunes. Instead,
Pfizer's name became attached to a dispute over eminent domain that went
all the way to the U.S. Supreme Court in a case that New London won on
legal grounds even as it lost in the court of public opinion.***



--
If you are flajim, herring, loogy, GC boater, johnson, topbassdog, rob,
or one of a half dozen others, you're wasting your time by trying to
*communicate* with me through rec.boats, because, well, you are among
the permanent members of my dumbfoch dumpster. As always, have a nice,
simple-minded day.